Sector News

Lilly to buy Versanis, adding to obesity drug pipeline

July 16, 2023
Life sciences

Founded in 2021 by Aditum Bio, Versanis is built around a drug licensed from Novartis. The antibody, called bimagrumab, is designed to block cellular communication via two types of protein regulators and is being studied in people who are overweight or obese.

Lilly’s planned purchase of Versanis is the latest in a monthlong M&A streak that’s included acquisitions of Dice Therapeutics, Sigilon Therapeutics and Emergence Therapeutics.

The dealmaking gives Lilly new drug candidates in areas of research it has prioritized, like immune diseases, cancer and obesity. Its recent success developing drugs for the latter condition has fueled a stock price surge that’s made it the most valuable pharmaceutical company in the world.

Lilly’s most advanced drug in testing for weight loss, an injection called Mounjaro, targets a hormone called GLP-1, similar to Novo Nordisk’s wildly popular diabetes and obesity drugs Ozempic and Wegovy. Another promising medicine that’s not as far along also targets GLP-1, as well as two other hormones. READ MORE

by Ned Pagliarulo

Source: biopharmadive.com

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach